By PPN Staff
Patients and providers seeking relief from the steadily rising costs of oncology drugs may have gotten some good news this week with the announcement that the FDA has approved bevacizumab-awwb (Mvasi), the first U.S. biosimilar approved for the treatment of cancer.
“Bringing new biosimilars to patients, especially for diseases where the cost of existing treatments can be high, is an important way to help spur competition that can lower health care costs and increase access to